 |
| "Kitten" in Munich |
Against a backdrop of shifting case law, evolving EU regulations, and the rise of the UPC, this year’s summit is a key place where originators, generics, biosimilars, biotech, regulators, and law firms come together to shape the future of IP strategy in Europe.
This year’s agenda features the following speakers:
In-House Counsel Highlights:
- James Horgan, Chief IP Counsel – Policy & Litigation, MSD
- Julia Pike, Global Head of IP, Sandoz
- Ana Gabarda, Director – Corporate Patent Counsel, Merck
- Toni Santamaria, SVP Intellectual Property & Legal, Adalvo
- Maurizio di Stasio, Senior Patent Counsel, Bayer
- Mathilde Rauline, Head of Greater Europe Patent Litigation, Sanofi
- Fleur Herrenschmidt, Chief Legal Officer, Norgine
- Natalia Wright, Associate General Patent Counsel, UCB
- Plus many more from Novartis, Amgen, BioNTech, Fresenius Kabi, Chiesi, Polpharma, Regeneron, and others
Judicial & Patent Office Faculty:
- Martin Schmidt, Technically Qualified Judge, UPC
- Roberto Romandini, Legal Member, Boards of Appeal, EPO
- Oliver Werner, Head of SPC Working Group, German PTO
- Patrick Purcell, Senior Patent Examiner, UK IPO
- Fergal Brady, Patent Examiner, Irish IPO
- Damien Filippini, Patent Engineer, INPI
- And more, providing direct insights into case law and procedural shifts
With over 50 senior in-house counsel, patent office examiners, and UPC judges, participants will gain a 360° view of the legal, regulatory, and competitive challenges driving exclusivity decisions across the life sciences sector.
New to the 2025 edition are the following topics:
- Unitary SPC developments: What a centralized SPC system means for exclusivity strategy.
- Patent quality across EPO & PTAB: Tackling unpredictability and enforcement challenges.
- AI in Life Sciences IP: Regulatory changes, FTO implications, and future-proofing strategy.
- Divisional patents in EU & US: Impact of Teva cases and FTC decisions.
- Bolar exemptions & safe harbor: Cross-jurisdictional differences shaping trial strategies.
- Second medical use & skinny labels: Navigating complex enforcement landscapes.
- Regulatory exclusivity reforms: New EU legislation, Tecfidera implications, and portfolio management.
- Antibody exclusivity: EPO vs USPTO comparisons, inventive step debates, and Amgen/Sanofi impact.
Also this year, IPKat readers are entitled to a 15% discount in the registration fee by using VIP code IPKATSM15 at checkout. For further information and to register, click here.
Do you want to reuse the IPKat content? Please refer to our
Policies section.
If you have any queries or requests for permission, please get in touch with the IPKat team.
Comments
Post a Comment
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html